Cargando…

Managing Waldenström’s macroglobulinemia with BTK inhibitors

Bruton’s tyrosine kinase (BTK) inhibition is one of the treatment standards for patients with relapsed/refractory Waldenström’s macroglobulinemia (WM) and for patients with WM who are unsuitable for immunochemotherapy (ICT). It offers deep and durable responses with a manageable safety profile that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buske, Christian, Jurczak, Wojciech, Salem, Joe-Elie, Dimopoulos, Meletios A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883164/ https://www.ncbi.nlm.nih.gov/pubmed/36402930 http://dx.doi.org/10.1038/s41375-022-01732-9

Ejemplares similares

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2021)

Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
por: Dogliotti, Irene, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

How to manage Waldenstrom's macroglobulinemia
por: Buske, C, et al.
Publicado: (2013)

Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
por: Muñoz, Javier, et al.
Publicado: (2022)

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
por: Papanota, Aristea-Maria, et al.
Publicado: (2019)

Treatment options for relapsed Waldenström's Macroglobulinemia
por: Grunenberg, Alexander, et al.
Publicado: (2019)

Waldenstrom macroglobulinemia: prognosis and management
por: Oza, A, et al.
Publicado: (2015)

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic
por: Talaulikar, Dipti, et al.
Publicado: (2020)

New developments in the management of Waldenström macroglobulinemia
por: Abeykoon, Jithma P, et al.
Publicado: (2017)

Waldenstrom’s Macroglobulinemia: An Update
por: Mazzucchelli, Maddalena, et al.
Publicado: (2018)

Waldenstrom macroglobulinemia: prognosis and management
por: Oza, A, et al.
Publicado: (2016)

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics
por: Dimopoulos, M. A., et al.
Publicado: (2016)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Khan, Abdullah Mohammad
Publicado: (2022)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Ababneh, Obada, et al.
Publicado: (2022)

Pseudohyperphosphatemia in Waldenstrom's Macroglobulinemia
por: Amalnath, S. D., et al.
Publicado: (2013)

Waldenström macroglobulinemia: biology, genetics, and therapy
por: Paludo, Jonas, et al.
Publicado: (2016)

Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors
por: Zhu, Jingjing, et al.
Publicado: (2023)

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate(TM) Trial
por: Trotman, Judith, et al.
Publicado: (2021)

Cutaneous macroglobulinosis with Waldenström macroglobulinemia
por: Hassab-El-Naby, Hussein M.M., et al.
Publicado: (2020)

Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management
por: Hobbs, Miriam, et al.
Publicado: (2020)

Waldenstrom's macroglobulinemia associated with eosinophilia
por: You, Eunkyoung, et al.
Publicado: (2013)

Genomic landscape of Waldenström's macroglobulinemia
por: Treon, Steven P., et al.
Publicado: (2019)

Bone localization of Waldenstrom’s macroglobulinemia
por: Daste, Camille, et al.
Publicado: (2023)

A prognostic index predicting survival in transformed Waldenström macroglobulinemia
por: Durot, Eric, et al.
Publicado: (2020)

Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination
por: Terpos, Evangelos, et al.
Publicado: (2021)

Waldenström macroglobulinemia treatment algorithm 2018
por: Gertz, Morie A.
Publicado: (2018)

Waldenstrom's Macroglobulinemia: A case report
por: Kolikkat, Nejima, et al.
Publicado: (2020)

Clinical Features of Waldenstrom Macroglobulinemia in Korea
por: Bang, Soo-Mee, et al.
Publicado: (2004)

Venetoclax in Previously Treated Waldenström Macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2022)

Pseudovitelliform Subfoveal Deposit in Waldenström's Macroglobulinemia
por: Brolly, Aurélie, et al.
Publicado: (2012)

Splenic re-irradiation for waldenstrőm’s macroglobulinemia
por: Wei, Zhou, et al.
Publicado: (2012)

Membranoproliferative glomerulonephritis complicating Waldenström’s macroglobulinemia
por: Kratochvil, David, et al.
Publicado: (2012)

CNS Vasculitis Associated with Waldenström Macroglobulinemia
por: Riangwiwat, Tanawan, et al.
Publicado: (2016)

Stiff-person Syndrome with Waldenström Macroglobulinemia
por: Horiuchi, Kazuhiro, et al.
Publicado: (2018)

Focal Segmental Glomerulosclerosis in Waldenström's Macroglobulinemia
por: Batra, Akshee, et al.
Publicado: (2020)

Chylothorax as an Initial Manifestation of Waldenström macroglobulinemia
por: Rodriguez Botero, Natalia, et al.
Publicado: (2020)

Waldenström's macroglobulinemia front line treatment
por: Tedeschi, Alessandra, et al.
Publicado: (2019)

HPV+ Oropharyngeal Cancer in Waldenström Macroglobulinemia
por: Raslan, Shahm, et al.
Publicado: (2023)

Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond
por: Zanwar, Saurabh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_87a0fsasuhg65h85kuro0u3dbm